Multiple Sclerosis

被引：37

作者：

Files, Daniel Kane ^{[1
]}

Jausurawong, Tani ^{[1
]}

Katrajian, Ruba ^{[1
]}

Danoff, Robert ^{[1
]}

机构：

[1] Aria Hlth, Emergency Med Residency, Combined Family Med, Family Med Residency, Philadelphia, PA 19114 USA

来源：

PRIMARY CARE | 2015年 / 42卷 / 02期

关键词：

Multiple sclerosis; Vitamin D; Epstein-Barr virus; Latitude; NATALIZUMAB; MANAGEMENT; DIAGNOSIS; TRIAL;

D O I：

10.1016/j.pop.2015.01.007

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Multiple sclerosis (MS) is a chronic, debilitating disease that can have devastating effects. Presentation varies widely in symptoms, pace, and progression. In addition to a thorough history and physical examination, diagnostic tools required to diagnose MS and exclude other diagnoses include MRI, evoked potential testing, and cerebrospinal fluid analysis. Although the disease is not curable presently, quality of life can be improved by minimizing the frequency and severity of disease burden. Disease modification, symptom management, preservation of function, and treatment of psychosocial issues are paramount to enhance the quality of life for the patient affected with MS.

引用

页码：159 / +

页数：18

共 36 条

[1] Neuroimaging in Multiple Sclerosis [J].

Ali, Eman N. ;

Buckle, Guy. L. .

NEUROLOGIC CLINICS, 2009, 27 (01) :203-+

[2]

[Anonymous], MS OV WHAT IS MULT S

[3]

[Anonymous], 2014, HLA DRB1 MAJ HIST CO

[4] Vitamin D and multiple sclerosis [J].

Ascherio, Alberto ;

Munger, Kassandra L. ;

Simon, K. Claire .

LANCET NEUROLOGY, 2010, 9 (06) :599-612

[5] CD40: Novel Association with Crohn's Disease and Replication in Multiple Sclerosis Susceptibility [J].

Blanco-Kelly, Fiona ;

Matesanz, Fuencisla ;

Alcina, Antonio ;

Teruel, Maria ;

Diaz-Gallo, Lina M. ;

Gomez-Garcia, Maria ;

Lopez-Nevot, Miguel A. ;

Rodrigo, Luis ;

Nieto, Antonio ;

Cardena, Carlos ;

Alcain, Guillermo ;

Diaz-Rubio, Manuel ;

de la Concha, Emilio G. ;

Fernandez, Oscar ;

Arroyo, Rafael ;

Martin, Javier ;

Urcelay, Elena .

PLOS ONE, 2010, 5 (07) :1-4

[6] Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy [J].

Bloomgren, Gary ;

Richman, Sandra ;

Hotermans, Christophe ;

Subramanyam, Meena ;

Goelz, Susan ;

Natarajan, Amy ;

Lee, Sophia ;

Plavina, Tatiana ;

Scanlon, James V. ;

Sandrock, Alfred ;

Bozic, Carmen .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (20) :1870-1880

[7]

Calabresi PA, 2004, AM FAM PHYSICIAN, V70, P1935

[8] Environmental factors and multiple sclerosis [J].

Ebers, George C. .

LANCET NEUROLOGY, 2008, 7 (03) :268-277

[9] Banting Lecture 2009: An Unfinished Journey: Molecular Pathogenesis to Prevention of Type 1A Diabetes [J].

Eisenbarth, George S. .

DIABETES, 2010, 59 (04) :759-774

[10] Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis [J].

Fox, Robert J. ;

Miller, David H. ;

Phillips, J. Theodore ;

Hutchinson, Michael ;

Havrdova, Eva ;

Kita, Mariko ;

Yang, Minhua ;

Raghupathi, Kartik ;

Novas, Mark ;

Sweetser, Marianne T. ;

Viglietta, Vissia ;

Dawson, Katherine T. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (12) :1087-1097

← 1 2 3 4 →